Data on neuraminidase inhibitors were made available

doi:10.1136/bmj.328.7438.523-a

BMJ 2004;328:523 (28 February), doi:10.1136/bmj.328.7438.523-a

Letter

Data on neuraminidase inhibitors were made available

The first 150 words of the full text of this article appear below.

EDITOR—In response to Symmonds et al,¹ F Hoffmann-La Rochewould like to clarify that data from studies WV15759/WV15871were made available to the National Institute for Clinical Excellence.

These were double blind, placebo controlled trials, conductedin children aged 6 or older and 12 or younger, to investigatethe efficacy and tolerability of oseltamivir in the treatmentof influenza among asthmatic children. Of the 355 children randomisedto treatment, 170 received oseltamivir 2 mg/kg and 164 receivedplacebo. Of these children, 179 had laboratory confirmed influenzainfection, which represented only 70% of the planned recruitmenttarget. This precluded any statistical demonstration of theprimary efficacy end point "time to freedom from illness" (incorporatingresolution of symptoms and a return to normal activity).

Among the outcomes of this study, a positive effect on forcedexpiratory volume in one second in the oseltamivir group wasseen, an observation that is . . . [Full text of this article]

Zoya Panahloo, senior medical adviser

United Kingdom F Hoffmann La Roche, Welwyn Garden City, Hertfordshire AL7 3AY zoya.panahloo@roche.com

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Article

Guidelines on neuraminidase inhibitors in children are not supported by evidence: Mkael Symmonds, Nicholas J Matheson, and Anthony Harnden
BMJ 2004 328: 227. [Extract] [Full Text]